Nektar Therapeutics is a San Francisco biopharmaceutical company developing immunotherapy drugs for autoimmune diseases and cancer. It last closed at $30.20 on Nov 20, down 7.19% on the day. The next earnings report for NKTR is expected around Thu, Mar 11, 2027, after the close. For the quarter ended Sep 2026, NKTR reported EPS of -$1.63 on revenue of $9.4M, with revenue down 20.4% from a year ago. Over its last 8 reports the stock moved an average of 2.8% the session after earnings. Over the last 12 months NKTR insiders bought $0 of stock on the open market and sold $2.5M, according to SEC Form 4 filings.
AI Auto Pilots
Is NKTR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NKTR.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on NKTRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
NKTR · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 22% below its 20 day and 48% below its 50 day average. It is 115% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the 52 week low at $30.13, and the nearest resistance the Pivot at $30.89.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 6.8%/day
Key levels
$109.0052 week high+260.9%
$64.96200 day average+115.1%
$58.39100 day average+93.3%
$44.6050 day average+47.7%
$39.10Swing high (Nov 11)+29.5%
$36.8320 day average+22.0%
$31.66Pivot R1+4.8%
$30.89Pivot+2.3%
$30.20Last close
$30.1352 week low−0.2%
$29.44Pivot S1−2.5%
Indicators
RSI (14)
23.44
Oversold below 30
Oversold
MACD
-2.95
Below its signal line
Bearish
Stochastic
0.5
Near the bottom of its range
Oversold
ADX (14)
35.4
Trending down
Williams %R
-99.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-306.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−18.9%
Change over 10 sessions
Bearish
ATR (14)
$2.05
Typical daily range, 6.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityNormal, 23.8%/day
Key levels
$109.0052 week high+260.9%
$64.96200 day average+115.1%
$58.39100 day average+93.3%
$44.6050 day average+47.7%
$39.10Swing high (Nov 11)+29.5%
$36.8320 day average+22.0%
$31.66Pivot R1+4.8%
$30.89Pivot+2.3%
$30.20Last close
$30.1352 week low−0.2%
$29.44Pivot S1−2.5%
Indicators
RSI (14)
26.49
Oversold below 30
Oversold
MACD
-8.72
Below its signal line
Bearish
Stochastic
2.7
Near the bottom of its range
Oversold
ADX (14)
28.1
Trending down
Williams %R
-99.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-111.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−56.7%
Change over 10 sessions
Bearish
ATR (14)
$7.18
Typical daily range, 23.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for NKTR
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how NKTR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow NKTR usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for NKTRHow many large options trades hit NKTR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in NKTR in the last 90 days.
From SEC Form 4 filings by NKTR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NKTR is in one of them and how their past NKTR trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company based in San Francisco, California. It researches and develops drugs that act on the immune system, with programs aimed at autoimmune diseases such as atopic dermatitis and at cancer. Its main drug candidate, rezpegaldesleukin, is designed to increase the activity of regulatory T cells to help restore immune balance. The company's drugs are still in development, and they are intended for people living with autoimmune and inflammatory conditions.